How would you handle recurring toxicity such as cytopenias for patients receiving subcutaneous pertuzumab/trastuzumab?

SQ HP doesn't cause cytopenias, and it would still be safe to administer SQ HP in the setting of cytopenias, so it hasn't had an impact on my utilization.

It would not be clear to what extent cytopenias are due to chemotherapy or to HER2 antibody therapy regardless of the route of administration. I would lower chemotherapy dose appropriately, or in early stage breast cancer, if granulocytopenia, would use hematopoietic growth factor therapy. If compli...

I don't anticipate substantial risk of cytopenias with pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injection versus the IV formulation. If the cytopenias occur concurrent with chemotherapy, I recommend making dose adjustments to the chemotherapy agent(s). If the cytopenias occur in ...